Active or prior autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent per treating physicians clinical judgment. Subjects with type  diabetes, vitiligo, psoriasis, hypothyroidism, or hyperthyroidism not requiring immunosuppressive medications are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent per treating physicians clinical judgment; subjects with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; patients with diabetes type , vitiligo, psoriasis, pure red cell aplasia, Goods syndrome or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease with reasonable possibility of clinically significant deterioration when receiving an immuno-stimulatory agent; subjects with type  diabetes mellitus, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
Active or prior autoimmune disease that might deteriorate with receiving an immunostimulatory agent. However, patients with diabetes type , vitiligo, psoriasis, or hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are eligible;
Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agents. Patients with diabetes type I, vitiligo, psoriasis, hypo or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible; replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent.
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; participants with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible
Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent; the following are not exclusions:\r\n* Patients with diabetes type I, vitiligo, hypo- or hyperthyroid diseases, or psoriasis not requiring systemic immunosuppressive treatment are eligible
